TECX
HEALTHCAREAvroBio Inc
$29.02-0.34 (-1.16%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TECX Today?
No stock-specific AI insight has been generated for TECX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.38$36.03
$29.02
Fundamentals
Market Cap$547M
P/E Ratio—
EPS$-4.05
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume237K
Avg Volume (10D)—
Shares Outstanding18.8M
TECX News
20 articles- Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 7, 2026
- Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth PlansYahoo Finance·May 1, 2026
- Tectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsYahoo Finance·Apr 23, 2026
- TD Asset Management Inc. Announces TD ETF DistributionsYahoo Finance·Mar 19, 2026
- Tectonic Therapeutic to Participate in March Investor ConferencesYahoo Finance·Mar 2, 2026
- Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Feb 26, 2026
- Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing BeginsMarketbeat·Feb 25, 2026
- Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the BoardYahoo Finance·Feb 23, 2026
- Daniel Lochner Bought 70% More Shares In Tectonic TherapeuticYahoo Finance·Feb 14, 2026
- Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026Yahoo Finance·Feb 11, 2026
- Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy RatingYahoo Finance·Dec 10, 2025
- Tectonic Therapeutic to Participate in December Investor ConferencesYahoo Finance·Dec 1, 2025
- Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Nov 6, 2025
- Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEFYahoo Finance·Oct 29, 2025
- Bullish Tectonic Therapeutic Insiders Loaded Up On US$61.2m Of StockYahoo Finance·Oct 12, 2025
- Tectonic Therapeutic to Participate in September Investor ConferencesYahoo Finance·Aug 28, 2025
- Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Aug 7, 2025
- Tectonic Therapeutic Joins Russell 3000® IndexYahoo Finance·Jun 30, 2025
- Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform RatingYahoo Finance·Jun 24, 2025
- We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business GrowthYahoo Finance·Jun 15, 2025
All 20 articles loaded
Price Data
Open$29.32
Previous Close$29.36
Day High$30.12
Day Low$28.80
52 Week High$36.03
52 Week Low$14.38
52-Week Range
$14.38$36.03
$29.02
Fundamentals
Market Cap$547M
P/E Ratio—
EPS$-4.05
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume237K
Avg Volume (10D)—
Shares Outstanding18.8M
About AvroBio Inc
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—